Rhinitis

Pipeline Programs

Companies

Clinical Trials

1 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

On Market (7)

Approved therapies currently available

ARNUITY ELLIPTAApproved

fluticasone furoate

GSK

inhalation2014

98M Part D

CLARITIN HIVES RELIEF REDITABApproved

loratadine

Bayer

oral1996

CLARITINApproved

loratadine

Bayer

oral1996

CLARITIN REDITABSApproved

loratadine

Bayer

oral1996

CHILDREN'S CLARITINApproved

loratadine

Bayer

oral2006

CLARITIN HIVES RELIEFApproved

loratadine

Bayer

oral1996

FLONASE SENSIMIST ALLERGY RELIEFApproved

fluticasone furoate

GSK

nasal2007

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

GSKLONDON, United Kingdom

5 programs

FluticasoneN/A1 trial

Levocetirizine IRT 5 mgPHASE_11 trial

Fluticasone furoatePHASE_31 trial

LevocetirizinePHASE_31 trial

Active Trials

NCT01420822Completed500Est. Aug 2014

NCT01376206Completed2,000Est. May 2011

NCT03555890Completed72Est. Sep 2018

+2 more trials

BayerLEVERKUSEN, Germany

2 programs

loratadinePhase 41 trial

Phenylephrine HClPhase 21 trial

Active Trials

NCT01330017Completed539Est. Jun 2011

NCT01469234Completed255Est. Nov 2011

MSDIreland - Ballydine

2 programs

LoratadinePhase 4

montelukastPhase 4

Sharp TherapeuticsPA - Pittsburgh

2 programs

LoratadinePhase 41 trial

montelukastPhase 41 trial

Active Trials

NCT00963573Completed100Est. Nov 2006

NCT00406094Unknown6Est. Dec 2009

ViiV HealthcareNC - Durham

9 programs

Fluticasone furoatePhase 3

LevocetirizinePhase 3

SB-705498Phase 2

Levocetirizine IRT 5 mgPhase 1

+4 more programs

InmunotekSpain - Madrid

3 programs

Allergen Immunotherapy ExtractPhase 31 trial

MG56 Mannosylated 500 subcutaneousPhase 21 trial

MM09 Mannosylated 5.000 subcutaneousPhase 21 trial

Active Trials

NCT02654223Completed180Est. Nov 2021

NCT02661854Unknown186Est. Jul 2020

NCT07348302Recruiting736Est. Jul 2029

Hanmi PharmaceuticalKorea - Seoul

1 program

HCP1102Phase 11 trial

Active Trials

NCT01651481Completed28Est. Dec 2012

UCB PharmaBelgium - Brussels

4 programs

levocetirizine or placeboN/A1 trial

Levocetirizine dihydrochloridePHASE_31 trial

levocetirizine dihydrochloridePHASE_31 trial

Levocetirizine dihydrochloridePHASE_41 trial

Active Trials

NCT01008592Terminated11Est. Sep 2010

NCT00525278Completed67Est. Oct 2003

NCT00524836Completed71Est. Feb 2004

+1 more trials

Allergy TherapeuticsUK - West Sussex

1 program

subcutaneous allergen immunotherapyN/A1 trial

Active Trials

NCT02949050Unknown40Est. Dec 2018

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

2028

2029

Bayerloratadine

Sharp Therapeuticsmontelukast

Sharp TherapeuticsLoratadine

UCB PharmaLevocetirizine dihydrochloride

InmunotekAllergen Immunotherapy Extract

GSKFluticasone furoate

GSKLevocetirizine

UCB Pharmalevocetirizine dihydrochloride

UCB PharmaLevocetirizine dihydrochloride

InmunotekMM09 Mannosylated 5.000 subcutaneous

InmunotekMG56 Mannosylated 500 subcutaneous

BayerPhenylephrine HCl

GSKLevocetirizine IRT 5 mg

Hanmi PharmaceuticalHCP1102

Allergy Therapeuticssubcutaneous allergen immunotherapy

Showing 15 of 18 trials with date data

Clinical Trials (18)

Total enrollment: 5,365 patients across 18 trials

NCT01469234 Bayerloratadine

A Study of Onset of Action of Loratadine and Fexofenadine in Participants With Seasonal Allergic Rhinitis (P08712)

Start: Oct 2011Est. completion: Nov 2011255 patients

Phase 4Completed

NCT00406094 Sharp Therapeuticsmontelukast

Singulair Use in Non-Allergic Rhinitis Eosinophil Syndrome (NARES)

Start: Nov 2006Est. completion: Dec 20096 patients

Phase 4Unknown

NCT00963573 Sharp TherapeuticsLoratadine

Efficacy & Safety of Loratadine-Betamethasone Oral Solution for Treatment of Severe Perennial Allergic Rhinitis in Children (Study P03428)

Start: Sep 2003Est. completion: Nov 2006100 patients

Phase 4Completed

NCT00521131 UCB PharmaLevocetirizine dihydrochloride

Evaluation of Efficacy and Safety of Levocetirizine to Subjects With Perennial Allergic Rhinitis to House Dust Mites

Start: Sep 2002Est. completion: May 2003453 patients

Phase 4Completed

NCT07348302 InmunotekAllergen Immunotherapy Extract

Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or Df

Start: Apr 2025Est. completion: Jul 2029736 patients

Phase 3Recruiting

NCT01622231 GSKFluticasone furoate

Study FFR116365, an Open-label Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis

Start: Jun 2012Est. completion: Nov 201261 patients

Phase 3Completed

NCT01563081 GSKLevocetirizine

Safety Study of Levocetirizine Oral Solution for Japanese Pediatrics

Start: Apr 2012Est. completion: Aug 201260 patients

Phase 3Completed

NCT00524836 UCB Pharmalevocetirizine dihydrochloride

Efficacy and Safety of Levocetirizine Versus Loratadine for the Treatment of Perennial Allergic Rhinitis

Start: Sep 2003Est. completion: Feb 200471 patients

Phase 3Completed

NCT00525278 UCB PharmaLevocetirizine dihydrochloride

To Evaluate the Efficacy and Safety of Levocetirizine Versus Loratadine for Treatment of Seasonal Allergic Rhinitis

Start: Aug 2003Est. completion: Oct 200367 patients

Phase 3Completed

NCT02661854 InmunotekMM09 Mannosylated 5.000 subcutaneous

Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Mite Allergy

Start: Jun 2016Est. completion: Jul 2020186 patients

Phase 2Unknown

NCT02654223 InmunotekMG56 Mannosylated 500 subcutaneous

Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy

Start: Dec 2015Est. completion: Nov 2021180 patients

Phase 2Completed

NCT01330017 BayerPhenylephrine HCl

Effects of Phenylephrine on Nasal Congestion in Participants With Seasonal Allergic Rhinitis (P08156 AM2)(Completed)

Start: Mar 2011Est. completion: Jun 2011539 patients

Phase 2Completed

NCT03555890 GSKLevocetirizine IRT 5 mg

Bioequivalence Study Between Levocetirizine Oral Disintegrating Tablet (ODT) and Levocetirizine Immediate Release Tablet (IRT)

Start: May 2018Est. completion: Sep 201872 patients

Phase 1Completed

NCT01651481 Hanmi PharmaceuticalHCP1102

Study to Evaluate the Pharmacokinetics and Safety of Singulair and Xyzal in Free Combination and Fixed-dose Combination

Start: Jul 2012Est. completion: Dec 201228 patients

Phase 1Completed

NCT02949050 Allergy Therapeuticssubcutaneous allergen immunotherapy

Corn Occupational Rhinitis SCIT Efficacy Study

Start: Aug 2016Est. completion: Dec 201840 patients

N/AUnknown

NCT01420822 GSKFluticasone

Special Drug Use Investigation for ALLERMIST (Long Term)

Start: Dec 2010Est. completion: Aug 2014500 patients

N/ACompleted

NCT01376206 GSKFluticasone

Drug Use Investigation for ALLERMIST

Start: Dec 2009Est. completion: May 20112,000 patients

N/ACompleted

NCT01008592 UCB Pharmalevocetirizine or placebo

The Effect of Levocetirizine on Inflammatory Mediators in Dermatographism

Start: Apr 2009Est. completion: Sep 201011 patients

N/ATerminated

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals

1 actively recruiting trials targeting 5,365 patients

10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.